Taiwan FDA OKs Heron Neutron Medical IND Application for Imaging Drug

MT Newswires Live

Yesterday

Heron Neutron Medical (TPE:7799) said Taiwan's Food and Drug Administration has in-principle approved its resubmitted investigational new drug (IND) application for F18 FBPA Injection, according to a Tuesday Taiwan Exchange filing.

Shares gained about 3% in Wednesday's late morning trade.

F18 FBPA is an imaging drug used in PET/CT scans to check tumors and test its safety and effectiveness.

The approval allows the company to proceed with Phase I and Phase II academic human clinical trials.

The IND was resubmitted on Dec. 8, 2025, and the company received notification of approval on Feb. 10, 2026.

Heron said no manufacturer worldwide has obtained regulatory approval for F18 FBPA, making the study a first-in-human trial.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610604468"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610604468\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610604468?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-11 12:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610604468","market":"sh","top_or_hot":-1,"title":"Taiwan FDA OKs Heron Neutron Medical IND Application for Imaging Drug","media":"MT Newswires Live","content":"<html><body><p> Heron Neutron Medical (TPE:7799) said Taiwan's Food and Drug Administration has in-principle approved its resubmitted investigational new drug (IND) application for F18 FBPA Injection, according to a Tuesday Taiwan Exchange filing.</p><p>Shares gained about 3% in Wednesday's late morning trade.</p><p>F18 FBPA is an imaging drug used in PET/CT scans to check tumors and test its safety and effectiveness.</p><p>The approval allows the company to proceed with Phase I and Phase II academic human clinical trials.</p><p>The IND was resubmitted on Dec. 8, 2025, and the company received notification of approval on Feb. 10, 2026.</p><p>Heron said no manufacturer worldwide has obtained regulatory approval for F18 FBPA, making the study a first-in-human trial.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Taiwan FDA OKs Heron Neutron Medical IND Application for Imaging Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTaiwan FDA OKs Heron Neutron Medical IND Application for Imaging Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-11 12:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Heron Neutron Medical (TPE:7799) said Taiwan's Food and Drug Administration has in-principle approved its resubmitted investigational new drug (IND) application for F18 FBPA Injection, according to a Tuesday Taiwan Exchange filing.</p><p>Shares gained about 3% in Wednesday's late morning trade.</p><p>F18 FBPA is an imaging drug used in PET/CT scans to check tumors and test its safety and effectiveness.</p><p>The approval allows the company to proceed with Phase I and Phase II academic human clinical trials.</p><p>The IND was resubmitted on Dec. 8, 2025, and the company received notification of approval on Feb. 10, 2026.</p><p>Heron said no manufacturer worldwide has obtained regulatory approval for F18 FBPA, making the study a first-in-human trial.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IND.AU","symbol_name":"Industrial Minerals Ltd","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2610604468","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610604468","pubTimestamp":1770782583,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Heron Neutron Medical  said Taiwan's Food and Drug Administration has in-principle approved its resubmitted investigational new drug  application for F18 FBPA Injection, according to a Tuesday Taiwan Exchange filing.Shares gained about 3% in Wednesday's late morning trade.F18 FBPA is an imaging drug used in PET/CT scans to check tumors and test its safety and effectiveness.The approval allows the company to proceed with Phase I and Phase II academic human clinical trials.The IND was resubmitted on Dec. 8, 2025, and the company received notification of approval on Feb. 10, 2026.Heron said no manufacturer worldwide has obtained regulatory approval for F18 FBPA, making the study a first-in-human trial.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IND.AU":"Industrial Minerals Ltd","BK7095":"多种金属与采矿","IND":"Xtrackers Nifty 500 India ETF"},"translate_title":"台湾FDA批准Heron Neutron Medical影像药物IND申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IND":1.5,"IND.AU":1},"content_text":"Heron Neutron Medical (TPE:7799) said Taiwan's Food and Drug Administration has in-principle approved its resubmitted investigational new drug (IND) application for F18 FBPA Injection, according to a Tuesday Taiwan Exchange filing.Shares gained about 3% in Wednesday's late morning trade.F18 FBPA is an imaging drug used in PET/CT scans to check tumors and test its safety and effectiveness.The approval allows the company to proceed with Phase I and Phase II academic human clinical trials.The IND was resubmitted on Dec. 8, 2025, and the company received notification of approval on Feb. 10, 2026.Heron said no manufacturer worldwide has obtained regulatory approval for F18 FBPA, making the study a first-in-human trial.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}